Akari Therapeutics PLC (NASDAQ:AKTX) Stock Has Average Price Target of $32.33 According to Brokerages

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $32.33.

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Akari Therapeutics in a research note on Friday, October 2nd. Alliance Global Partners upgraded Akari Therapeutics to a “strong-buy” rating in a research note on Friday, September 18th. Wall Street Zen raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Finally, Maxim Group raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Monday, July 20th.

Akari Therapeutics Stock Down 6.9%

Shares of AKTX stock opened at $7.13 on Wednesday. Akari Therapeutics has a 52 week low of $3.02 and a 52 week high of $29.32. The firm’s 50-day simple moving average is $9.15 and its two-hundred day simple moving average is $9.01.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company’s research centers on complement-system and leukotriene biology, which are involved in immune responses and inflammation. Its lead investigational product is nomacopan, a recombinant protein designed to inhibit complement component C5 and leukotriene B4. Akari is also developing PAS-nomacopan, a longer-acting version intended to extend the therapy’s duration of action.